A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants

Phase 1Active Not RecruitingNCT06953934

AbbVie8 enrolled

Overview

The main objective of this study is to assess the safety and tolerability of ABBV-932 in healthy adult male participants.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Healthy Volunteer

Interventions

ABBV-932DRUG

Oral Capsule

Eligibility

Sex: MALEMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Body Mass Index (BMI) ≥ 18.0 to ≤ 29.9.0 kg/m\^2 after rounding to the tenths decimal. BMI is calculated as weight in kg divided by the square of height measured in meters. * Male participant who is not considering fathering a child or donating sperm during the study and for 100 days after the study drug administration * A condition of general good health, based upon the results of a medical history, physical exam Exclusion Criteria: * Has not participated in another \[14C\] absorption, distribution, metabolism, excretion (ADME) study with a radiodose above 0.1 MBq in the period of 12 months prior to screening. * Use of any medications/products known to alter drug absorption, metabolism, or excretion processes, within 30 days or within a period defined by 5 half-lives, whichever is longer, prior to study drug administration. * Prior exposure to ABBV-932 or cariprazine within the past 90 days.

Locations (1)

ICON Clinical Research /ID# 270490

Groningen, Netherlands